公开(公告)号：US20170080358A1

公开(公告)日：2017-03-23

申请号：US15367640

申请日：2016-12-02

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Sophia Hober

IPC: B01D15/38 ,  C07K16/06 ,  B01J20/289 ,  C07K14/00 ,  B01J20/24

CPC classification number: B01D15/3809 ,  B01J20/24 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3244 ,  B01J2220/44 ,  B01J2220/52 ,  C07K1/22 ,  C07K14/001 ,  C07K14/195 ,  C07K14/31 ,  C07K16/065 ,  Y10S530/81 ,  Y10S530/825

Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

公开(公告)号：US20190218265A1

公开(公告)日：2019-07-18

申请号：US16328058

申请日：2017-09-05

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Sophia Hober ,  Sara Kanje ,  Johan Nilvebrant

IPC: C07K14/47 ,  C07K1/22

CPC classification number: C07K14/4728 ,  C07K1/22 ,  C07K14/31 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/705

Abstract: The present invention is within the field of protein engineering and purification. The invention relates to a target-binding polypeptide mutant of an IgG binding polypeptide, such as Protein A, Protein G, Protein L or Protein M, comprising a metal binding motif. More closely the invention relates to an Fc binding ligand comprising an engineered protein based on the Protein A derived Z domain, to which a calcium binding EF-loop has been introduced.